| ［1］ |
中华医学会皮肤性病学分会, 中国医师协会皮肤科医师分会. 中国中重度特应性皮炎诊疗临床路径专家共识（2023版）［J］. 中华皮肤科杂志, 2023,56（11）:1000⁃1007. DOI: 10.35541/cjd.20230247.
|
| ［2］ |
Furue M, Furue M. OX40L⁃OX40 signaling in atopic dermatitis［J］. J Clin Med, 2021,10（12）:2578. DOI: 10.3390/jcm10122578.
|
| ［3］ |
Fu N, Xie F, Sun Z, et al. The OX40/OX40L axis regulates T follicular helper cell differentiation: implications for autoimmune diseases［J］. Front Immunol, 2021,12:670637. DOI: 10.3389/fimmu.2021.670637.
|
| ［4］ |
Elsner JS, Carlsson M, Stougaard JK, et al. The OX40 axis is associated with both systemic and local involvement in atopic dermatitis［J］. Acta Derm Venereol, 2020,100（6）:adv00099. DOI: 10.2340/00015555⁃3452.
|
| ［5］ |
中国医师协会皮肤科医师分会, 中华医学会皮肤性病学分会, 中国医疗保健国际交流促进会皮肤医学分会, 等. 特应性皮炎治疗药物应用管理专家共识（2024版）［J］. 中华皮肤科杂志, 2024,57（2）:97⁃108. DOI: 10.35541/cjd.20230358.
|
| ［6］ |
Nakahara T, Kido⁃Nakahara M, Tsuji G, et al. Basics and recent advances in the pathophysiology of atopic dermatitis［J］. J Dermatol, 2021,48（2）:130⁃139. DOI: 10.1111/1346⁃8138.15664.
|
| ［7］ |
Wu Y, Gu C, Wang S, et al. Serum biomarker⁃based endotypes of atopic dermatitis in China and prediction for efficacy of dupilumab［J］. Br J Dermatol, 2023,188（5）:649⁃660. DOI: 10. 1093/bjd/ljad032.
|
| ［8］ |
Fu Y, Lin Q, Zhang Z, et al. Therapeutic strategies for the costimulatory molecule OX40 in T⁃cell⁃mediated immunity［J］. Acta Pharm Sin B, 2020,10（3）:414⁃433. DOI: 10.1016/j.apsb. 2019.08.010.
|
| ［9］ |
Gajdasik DW, Gaspal F, Halford EE, et al. Th1 responses in vivo require cell⁃specific provision of OX40L dictated by environmental cues［J］. Nat Commun, 2020,11（1）:3421. DOI: 10.1038/s41467⁃020⁃17293⁃3.
|
| ［10］ |
Murata K, Ishii N, Takano H, et al. Impairment of antigen⁃presenting cell function in mice lacking expression of OX40 ligand［J］. J Exp Med, 2000,191（2）:365⁃374. DOI: 10.1084/jem. 191.2.365.
|
| ［11］ |
Hoshino A, Tanaka Y, Akiba H, et al. Critical role for OX40 ligand in the development of pathogenic Th2 cells in a murine model of asthma［J］. Eur J Immunol, 2003,33（4）:861⁃869. DOI: 10.1002/eji.200323455.
|
| ［12］ |
Yi K, Jo S, Song W, et al. Analysis of single⁃cell transcriptome and surface protein expression in ankylosing spondylitis Identifies OX40⁃positive and glucocorticoid⁃induced tumor necrosis factor receptor⁃positive pathogenic Th17 cells［J］. Arthritis Rheumatol, 2023,75（7）:1176⁃1186. DOI: 10.1002/art. 42476.
|
| ［13］ |
Kumari R, Chakraborty S, Jain R, et al. Inhibiting OX40 restores regulatory T⁃cell function and suppresses inflammation in pulmonary sarcoidosis［J］. Chest, 2021,160（3）:969⁃982. DOI: 10.1016/j.chest.2021.04.032.
|
| ［14］ |
Kuang Z, Jing H, Wu Z, et al. Development and characterization of a novel anti⁃OX40 antibody for potent immune activation［J］. Cancer Immunol Immunother, 2020,69（6）:939⁃950. DOI: 10. 1007/s00262⁃020⁃02501⁃2.
|
| ［15］ |
Fujita T, Ukyo N, Hori T, et al. Functional characterization of OX40 expressed on human CD8+ T cells［J］. Immunol Lett, 2006,106（1）:27⁃33. DOI: 10.1016/j.imlet.2006.04.001.
|
| ［16］ |
Guttman⁃Yassky E, Croft M, Geng B, et al. The role of OX40 ligand/OX40 axis signalling in atopic dermatitis［J］. Br J Dermatol, 2024,191（4）:488⁃496. DOI: 10.1093/bjd/ljae230.
|
| ［17］ |
Seshasayee D, Lee WP, Zhou M, et al. In vivo blockade of OX40 ligand inhibits thymic stromal lymphopoietin driven atopic inflammation［J］. J Clin Invest, 2007,117（12）:3868⁃3878. DOI: 10.1172/JCI33559.
|
| ［18］ |
Murakami⁃Satsutani N, Ito T, Nakanishi T, et al. IL⁃33 promotes the induction and maintenance of Th2 immune responses by enhancing the function of OX40 ligand［J］. Allergol Int, 2014,63（3）:443⁃455. DOI: 10.2332/allergolint.13⁃OA⁃0672.
|
| ［19］ |
Guttman⁃Yassky E, Pavel AB, Zhou L, et al. GBR 830, an anti⁃OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis［J］. J Allergy Clin Immunol, 2019,144（2）:482⁃493. DOI: 10.1016/j.jaci.2018.11.053.
|
| ［20］ |
Rewerska B, Sher LD, Alpizar S, et al. Phase 2b randomized trial of OX40 inhibitor telazorlimab for moderate⁃to⁃severe atopic dermatitis［J］. J Allergy Clin Immunol Glob, 2024,3（1）:100195. DOI: 10.1016/j.jacig.2023.100195.
|
| ［21］ |
Guttman⁃Yassky E, Simpson EL, Reich K, et al. An anti⁃OX40 antibody to treat moderate⁃to⁃severe atopic dermatitis: a multicentre, double⁃blind, placebo⁃controlled phase 2b study［J］. Lancet, 2023,401（10372）:204⁃214. DOI: 10.1016/S0140⁃6736（22）02037⁃2.
|
| ［22］ |
Guttman⁃Yassky E, Simpson E, Esfandiari E, et al. Rocatinlimab: a novel T⁃cell rebalancing therapy targeting the OX40 receptor in atopic dermatitis［J］. Dermatol Ther （Heidelb）, 2025,15（11）:3153⁃3171. DOI: 10.1007/s13555⁃025⁃01492⁃1.
|
| ［23］ |
Weidinger S, Bieber T, Cork MJ, et al. Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti⁃OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase Ⅱa randomized placebo⁃controlled trial［J］. Br J Dermatol, 2023,189（5）:531⁃539. DOI: 10.1093/bjd/ljad240.
|
| ［24］ |
Weidinger S, Blauvelt A, Papp KA, et al. Phase 2b randomized clinical trial of amlitelimab, an anti⁃OX40 ligand antibody, in patients with moderate⁃to⁃severe atopic dermatitis［J］. J Allergy Clin Immunol, 2024:S0091⁃6749（24）01175⁃8. DOI: 10.1016/j.jaci.2024.10.031.
|
| ［25］ |
Bieber T, Katoh N, Simpson EL, et al. Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials［J］. J Dermatolog Treat, 2023,34（1）:2161812. DOI: 10.1080/09546634.2022.2161812.
|
| ［26］ |
López⁃Abente J, Bernaldo⁃de⁃Quirós E, Camino M, et al. Immune dysregulation and Th2 polarization are associated with atopic dermatitis in heart⁃transplant children: a delicate balance between risk of rejection or atopic symptoms［J］. Am J Transplant, 2019,19（5）:1536⁃1544. DOI: 10.1111/ajt.15245.
|
| ［27］ |
Xiao X, Gong W, Demirci G, et al. New insights on OX40 in the control of T cell immunity and immune tolerance in vivo［J］. J Immunol, 2012,188（2）:892⁃901. DOI: 10.4049/jimmunol.110 1373.
|
| ［28］ |
Saghari M, Gal P, Gilbert S, et al. OX40L inhibition suppresses KLH⁃driven immune responses in healthy volunteers: a randomized controlled trial demonstrating proof⁃of⁃pharmacology for KY1005［J］. Clin Pharmacol Ther, 2022,111（5）:1121⁃1132. DOI: 10.1002/cpt.2539.
|
